REGN

805.93

0.30% 2.45

Dopo l'orario di chiusura: 805.93

Regeneron Pharmaceuticals Inc (REGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché REGN Giù? Forum Previsione

Precedente Chiudi:

$803.48

Aprire:

$801.76

Volume 24 ore:

541.27K

Relative Volume:

0.56

Capitalizzazione di mercato:

$82.97B

Reddito:

$14.92B

Utile/perdita netta:

$4.42B

Rapporto P/E:

19.64

EPS:

41.0422

Flusso di cassa netto:

$3.79B

1 W Prestazione:

-0.26%

1M Prestazione:

+19.10%

6M Prestazione:

+1.56%

1 anno Prestazione:

+38.86%

Intervallo 1D:

$795.73

$813.18

Intervallo di 1 settimana:

$784.61

$815.80

Portata 52W:

$541.00

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare (1082)

Industria

Biotechnology (606)

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Dipendente

15,410

Cinguettio

@regeneron

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-31	Ripresa	Piper Sandler	Overweight
2026-03-06	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	BofA Securities	Underperform → Buy
2025-12-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Iniziato	HSBC Securities	Buy
2025-11-24	Ripresa	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Ripresa	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Overweight
2021-12-07	Ripresa	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Ripresa	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Ripresa	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

04:39 AM

Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS

04:39 AM

12:26 PM

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners - MarketBeat

08:49 AM

06:37 AM

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating - marketscreener.com

06:37 AM

06:34 AM

Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:34 AM

05:36 AM

Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

05:36 AM

04:04 AM

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:04 AM

03:38 AM

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

03:38 AM

Aug 16, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mykxlg.com

Aug 16, 2026

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 16, 2026

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 16, 2026

Aug 15, 2026

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView

Aug 15, 2026

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments - MarketBeat

Aug 15, 2026

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story - simplywall.st

Aug 15, 2026

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy - MarketBeat

Aug 15, 2026

Aug 14, 2026

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 14, 2026

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - The Motley Fool

Aug 14, 2026

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - finance.yahoo.com

Aug 14, 2026

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines - finance.biggo.com

Aug 14, 2026

If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga

Aug 14, 2026

Regeneron Genetics Center's Andy Deubler: The AI-Era Genomics Race Will Be Decided by Curation, Not Volume - finance.biggo.com

Aug 14, 2026

The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class ... - Caledonian Record

Aug 14, 2026

BMS builds big in Texas; Regeneron backs would-be rival - Pharma Voice

Aug 14, 2026

Bernstein raises Regeneron stock price target to $756 on Eylea beat - Investing.com Canada

Aug 14, 2026

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating - marketscreener.com

Aug 14, 2026

Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits

Aug 14, 2026